Autologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells. It is also a cell therapy being investigated by Caladrius...
- Mechanism
- Curator reviewed · 1 reference
Autologous peripheral blood-derived CD34+ cells have potential tissue repair ability in part due to its anti-inflammatory function which were demonstrated in pre-clinical models, including one of lung inflammation. Due to the pre-programmed tissue repair effects mediated by anti-inflammatory and pro-angiogenic functions of these cells, this cell therapy is currently being investigated against COVID-19-induced lung damage in recovered adult patients that still are experiencing hypoxia and require supplemental oxygen.
- First approval
- European Union, 2020
- Also known as
- CD34+ Cells · CLBS119
- Code names
- Autologous peripheral blood-derived CD34+ cells
- Brand names
Resolves to
What you can answer from here — as of July 08, 2026
Which drugs share a target with Autologous peripheral blood-derived CD34+ cells, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account